Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Feb;52(2):e13699.
doi: 10.1111/eci.13699. Epub 2021 Nov 8.

Changes of lipoprotein(a) levels with endogenous steroid hormones

Affiliations
Multicenter Study

Changes of lipoprotein(a) levels with endogenous steroid hormones

Elena Tessitore et al. Eur J Clin Invest. 2022 Feb.

Abstract

Background: Lipoprotein(a) [Lp(a)] is an LDL-like molecule that is likely causal for cardiovascular events and Lp(a) variability has been shown to be mostly of genetic origin. Exogenous hormones (hormone replacement therapy) seem to influence Lp(a) levels, but the impact of endogenous hormone levels on Lp(a) is still unknown. The aim of the study was to assess the effect of endogenous steroid hormone metabolites on Lp(a).

Methods: Lipoprotein(a) levels were measured in 1,021 participants from the Swiss Kidney Project on Genes in Hypertension, a family-based, multicentre, population-based prospective cohort study. Endogenous levels of 28 steroid hormone precursors were measured in 24-h urine collections from 883 individuals. Of the participants with Lp(a) data, 1,011 participants had also genotypes available.

Results: The participants had an average age of 51 years and 53% were female. Median Lp(a) levels were 62 mg/L, and the 90th percentile was 616 mg/L. The prevalence of a Lp(a) elevation ≥700 mg/L was 3.2%. Forty-three per cent of Lp(a) variability was explained respectively by: age (2%, p < .001), LDL-C (1%, p = .001), and two SNPs (39%, p value<2⋅10-16 ). Of the 28 endogenous steroid hormones assessed, androstenetriol, androsterone, 16α-OH-DHEA and estriol were nominatively associated with serum Lp(a) levels in univariable analyses and explained 0.4%-1% of Lp(a) variability, but none of them reached significance in multivariable models.

Conclusions: In this contemporary population-based study, the prevalence of a Lp(a) elevation ≥700 mg/L was 3.2%. The effect of endogenous steroid hormone levels of Lp(a) variability was small at best, suggesting a negligible impact on the wide range of Lp(a) variability.

Keywords: cardiovascular risk; endogenous hormones; lipoprotein (a).

PubMed Disclaimer

Conflict of interest statement

FM is national PI of a clinical study by Novartis on Lp(a) lowering, GE is investigator of the same study and has received research grants, consulting, and speaking fees (minor) from Amgen, Boehringer, Daiichi‐Sankyo, MSD, Novartis, Recordati, Sanofi, Servier. MP has received consultancy and speaking fees from Novo Nordisk and Astellas.

Figures

FIGURE 1
FIGURE 1
Associations of different variables with Lp(a) concentrations in 750 subjects. Associations of different variables with Lp(a) concentrations in 750 subjects. Multivariate regression analysis, with linear mixed‐effects kinship models using maximum likelihood estimations were used. The β‐coefficients were scaled to Lp(a) levels in mg/L (fixed effects). A total of 750 participants had complete record for all characteristics, 52% of Lp(a) variability is explained by all those variables together, along with the family relatedness. Only age, LDL‐C, rs10455872 and rs3798220 are statistically significant with a variability of Lp(a) in mg/L, respectively, of 14 mg/L, 21 mg/L, 93.9 mg/L and 87.4 mg/L. Family relatedness explained up to 138 mg/L Lp(a) variability. Model residual error is 51.5 mg/L. p values: *** <.001 ** <.01 * < .05

Similar articles

References

    1. Maranhão RC, Carvalho PO, Strunz CC, Pileggi F. Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol. 2014;103(1):76‐84. - PMC - PubMed
    1. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol. 1998;82(12A):57U‐66U. discussion 86U. - PubMed
    1. Luc G, Bard JM, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME study. Atherosclerosis. 2002;163(2):377‐384. - PubMed
    1. Smith GD, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1‐22. - PubMed
    1. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844‐2853. - PMC - PubMed

Publication types